As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.
17 Analysts have issued a Terns Pharmaceuticals Inc forecast:
17 Analysts have issued a Terns Pharmaceuticals Inc forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -109 -109 |
9%
9%
|
|
| EBIT (Operating Income) EBIT | -108 -108 |
8%
8%
|
|
| Net Profit | -94 -94 |
7%
7%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.
| Head office | United States |
| CEO | Amy Burroughs |
| Employees | 59 |
| Founded | 2017 |
| Website | ternspharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


